Rich66
06-22-2011, 02:26 PM
http://www.marketwatch.com/story/immunocellular-therapeutics-to-present-at-2nd-world-cancer-vaccines-summit-2011-06-22?reflink=MW_news_stmp
The data shows 6 out of the 16 (37.6%) newly diagnosed patients who received ICT-107 continue to show no tumor recurrence, with 3 of these patients (18.8%) remaining disease-free for almost four years while the other 3 patients have gone more than 2 and a half years disease-free. No treatment related serious adverse events have been observed to date.
The data shows 6 out of the 16 (37.6%) newly diagnosed patients who received ICT-107 continue to show no tumor recurrence, with 3 of these patients (18.8%) remaining disease-free for almost four years while the other 3 patients have gone more than 2 and a half years disease-free. No treatment related serious adverse events have been observed to date.